KAI Pharmaceuticals Initiates Phase 2b Clinical Study of KAI-9803 in Heart Attack Patients

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced today the enrollment of the first patient in the Company’s Phase 2b efficacy study of KAI-9803, KAI’s proprietary, first-in-class inhibitor of the delta protein k... [more]

View complete Press Release article